News
LITS
0.9069
-7.94%
-0.0782
AI Price Prediction: Grok Prices Solana, Cardano and Litecoin for 2028. Which Gains the Most?
24/7 Wall St. · 1d ago
Lite Strategy reports Q1 results
Seeking Alpha · 2d ago
Lite Strategy Q1 EPS $0.48 Up From $(0.12) YoY
Benzinga · 2d ago
Press Release: Lite Strategy Reports Fiscal 2027 First Quarter Financial Results
Dow Jones · 2d ago
Weekly Report: what happened at LITS last week (1102-1106)?
Weekly Report · 3d ago
Lite Strategy, Inc. Reports Cashless Exercise of 517,509 Advisory Warrants by Green Dragon Investments LLC
NASDAQ · 11/03 23:11
Lite Strategy Reports Unregistered Equity Securities Issuance
TipRanks · 11/03 22:00
Weekly Report: what happened at LITS last week (1026-1030)?
Weekly Report · 11/02 09:15
Weekly Report: what happened at LITS last week (1019-1023)?
Weekly Report · 10/26 09:15
Weekly Report: what happened at LITS last week (1012-1016)?
Weekly Report · 10/19 09:15
Weekly Report: what happened at LITS last week (1005-1009)?
Weekly Report · 10/12 09:16
Weekly Report: what happened at LITS last week (0928-1002)?
Weekly Report · 10/05 09:16
Lite Strategy GAAP EPS of -$2.06
Seeking Alpha · 09/29 13:58
*Lite Strategy: Primary Objective Is to Grow LTC Holdings Per Shr Through Active Management of Treasury >LITS
Dow Jones · 09/29 12:32
*Lite Strategy Deployed $100 M to Acquire Over 900,000 LTC >LITS
Dow Jones · 09/29 12:32
*Lite Strategy Held 832,716 LTC as of June 30 >LITS
Dow Jones · 09/29 12:32
Press Release: Lite Strategy Reports Fiscal Year 2026 Financial Results
Dow Jones · 09/29 12:30
Lite Strategy Q4 EPS $(0.38) Up From $(0.40) YoY
Benzinga · 09/28 21:56
Lite Strategy files to sell 1.89M shares of common stock for holders
TipRanks · 09/28 20:40
Lite Strategy Files Prospectus For Offering 1.889M Common Shares On Behalf Of Selling Shareholders
Benzinga · 09/28 20:38
More
Webull provides a variety of real-time LITS stock news. You can receive the latest news about Lite Strategy Inc through multiple platforms. This information may help you make smarter investment decisions.
About LITS
Lite Strategy, Inc. is a pharmaceutical company focused on developed and differentiated cancer therapies. The Company's drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, zandelisib, an oral, once-daily, selective PI3Kd inhibitor. CDK9 functions in cell cycle regulation, and its modulation in cancer and autoimmune diseases. It is a transcriptional regulator of the myeloid leukemia cell differentiation protein (Mcl-1). Zandelisib is an oral, once-daily, selective PI3Kd inhibitor that is developed for the treatment of indolent B-cell lymphomas. Its approach to pre-clinical drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address medical needs. It holds Litecoin (LTC) tokens as a primary asset as part of an institutional treasury. LTC is an open source, global payment network that is decentralized without any central authorities.